

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: Benjamin OSHLACK *et al.*
Serial No.: 10/700,906
Patent No. 7,682,632
Filed: November 4, 2003
For: **TAMPER-RESISTANT ORAL OPIOID AGONIST
FORMULATIONS**
Docket No.: 200.1133CON5

Mail Stop: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 19, 2010

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.323

Sir:

In accordance with 37 C.F.R. § 1.323, Applicants hereby request that the U.S. Patent and Trademark Office issue a Certificate of Correction for the above-identified patent, adding the following section on the title page after item (65):

Related U.S. Application Data

- (63) Continuation of application No. 09/781,081, filed on
Feb. 8, 2001, now Pat. No. 6,696,088.
- (60) Provisional application No. 60/181,369, filed on Feb. 8, 2000.

Applicants submit that the omission of the Related U.S. Application Data section on the title page of the patent is a mistake “incurred through the fault of the Patent and Trademark Office, [and] is clearly disclosed by the records of the Office” as set forth in 35 U.S.C. § 254.

The Filing Receipt mailed by the U.S. Patent and Trademark Office on September 28, 2004, and the Updated Filing Receipt mailed by the U.S. Patent and Trademark Office on September 28, 2004, for the present application both recited in the “Domestic Priority data as claimed by applicant” sections that

This application is a CON of 09/781,081 02/08/2001 PAT 6,696,088 which claims benefit of 60/181,369 02/08/2000.

A copy of the Filing Receipt is attached as Appendix A; and a copy of the Updated Filing Receipt is attached as Appendix B.

The title page of the initial publication of the application (US 2006/0039970 A1) contained a Related U.S. Application Data section reciting:

Related U.S. Application Data

(63) Continuation of application No. 09/781,081, filed on Feb. 8, 2001, now Pat. No. 6,696,088.

(60) Provisional application No. 60/181,369, filed on Feb. 8, 2000.

A copy of the title page of the initial publication is attached as Appendix C.

The title page of the republication of the application (US 2008/0305167 A2) contained a Related U.S. Application Data section reciting:

Related U.S. Application Data

(63) Continuation of application No. 09/781,081, filed on Feb. 8, 2001, now Pat. No. 6,696,088, Feb. 24, 2004, which is a continuation application No. 60/181,369, filed on Feb. 8, 2000, now expired.

A copy of the title page of the republication of the application is attached as Appendix D.


Applicants note that the priority to application No. 09/781,081, filed on Feb. 8, 2001, and application No. 60/181,369, filed on Feb. 8, 2000, was claimed by the Applicants, e.g., in the Application Data Sheet 37 CFR 1.76 (PTO/SB/14) form filed by undersigned on August 26, 2008. According to the USPTO guidance, "providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. ... 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification." PTO/SB/14. A copy of the filed form is attached as Appendix E.

Accordingly, Applicants submit that the omission of the Related U.S. Application Data section on the title page of the present patent is a mistake "incurred through the fault of the Patent and Trademark Office, [and] is clearly disclosed by the records of the Office" as set forth in 35 U.S.C. § 254, and request that the U.S. Patent and Trademark Office issue a Certificate of

Correction for the above-identified patent adding the Related U.S. Application Data section after item (65) on the title page of the patent.

No fee is believed to be due for this correction. If any fees are deemed necessary in connection with this request, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-0552.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
Oleg Ioselevich, Reg. No. 56,963

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

APPENDIX A



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address COMMISSIONER FOR PATENTS
 P.O. Box 150
 Alexandria, Virginia 22313-1150
 www.uspto.gov

APPL NO.	FILING OR 371 (5) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/700,906	11/04/2003	1615	1060	200.1133CON5	3	13	2

DAVIDSON, DAVIDSON & KAPPEL, LLC
 14th Floor
 485 Seventh Avenue
 New York, NY 10018

RECEIVED
 SEP 30 2004

CONFIRMATION NO. 1129

FILING RECEIPT

OC000000013919308

DAVIDSON, DAVIDSON & KAPPEL

Date Mailed: 09/28/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Benjamin Oshlack, New York, NY;
 Curtis Wright, Norwalk, CT;
 J. David Haddox, Upper Stepney, CT;

Power of Attorney: The patent practitioners associated with Customer Number **23280**.

Domestic Priority data as claimed by applicant

This application is a CON of 09/781,081 02/08/2001 PAT 6,696,088
 which claims benefit of 60/181,369 02/08/2000

Foreign Applications

If Required, Foreign Filing License Granted: 09/27/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/700,906

Projected Publication Date: To Be Determined - pending completion of Omitted Items

Non-Publication Request: No

Early Publication Request: No

Title

Tamper-resistant oral opioid agonist formulations

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

APPENDIX B



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/700,906	11/04/2003	1615	1060	200.1133CON5	3	13	2

DAVIDSON, DAVIDSON & KAPPEL, LLC
 14th Floor
 485 Seventh Avenue
 New York, NY 10018

CONFIRMATION NO. 1129

UPDATED FILING RECEIPT



OC000000017457286

NOV 18 2005

Date Mailed: 11/15/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Benjamin Oshlack, New York, NY;
 Curtis Wright, Norwalk, CT;
 J. David Haddox, Upper Stepney, CT;

Power of Attorney: The patent practitioners associated with Customer Number 23280.

Domestic Priority data as claimed by applicant

This application is a CON of 09/781,081 02/08/2001 PAT 6,696,088
 which claims benefit of 60/181,369 02/08/2000

Foreign Applications

If Required, Foreign Filing License Granted: 09/27/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/700,906**

Projected Publication Date: 02/23/2006

Non-Publication Request: No

Early Publication Request: No

and esp/ep

Title

Tamper-resistant oral opioid agonist formulations

Preliminary Class

424

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

APPENDIX C



US 20060039970A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2006/0039970 A1****Oshlack et al.**(43) **Pub. Date: Feb. 23, 2006**(54) **TAMPER-RESISTANT ORAL OPIOID
AGONIST FORMULATIONS**

(60) Provisional application No. 60/181,369, filed on Feb. 8, 2000.

(76) Inventors: Benjamin Oshlack, New York, NY
(US); Curtis Wright, Norwalk, CT
(US); J. David Haddox, Upper
Stepney, CT (US)**Publication Classification**(51) **Int. Cl.**
A61K 9/44 (2006.01)
A61K 9/20 (2006.01)
(52) **U.S. Cl.** 424/465; 424/10.2Correspondence Address:
DAVIDSON, DAVIDSON & KAPPEL, LLC
14th Floor
485 Seventh Avenue
New York, NY 10018 (US)(57) **ABSTRACT**(21) Appl. No.: **10/700,906**(22) Filed: **Nov. 4, 2003****Related U.S. Application Data**(63) Continuation of application No. 09/781,081, filed on
Feb. 8, 2001, now Pat. No. 6,696,088.

Controlled-release dosage forms comprising opioid agonist and opioid antagonist are provided. The dosage forms release the opioid antagonist and the opioid agonist in a controlled-release manner. The dosage forms may be used to provide pain relief to patients while reducing the side effects associated with opioid agonists.

APPENDIX D



US 20080305167A2

(19) **United States**(10) **Pub. No.: US 2008/0305167 A2**(12) **Patent Application Publication**(43) **Pub. Date: Dec. 11, 2008****Oshlack et al.****REPUBLICATION**(54) **TAMPER-RESISTANT ORAL OPIOID
AGONIST FORMULATIONS****Related U.S. Application Data**(75) Inventors: **Benjamin Oshlack**, New York, NY
(US); **Curtis Wright**, Norwalk, CT
(US); **J. David Haddox**, Upper Stepney,
CT (US)(63) Continuation of application No. 09/781,081, filed on
Feb. 8, 2001, now Pat. No. 6,696,088, Feb. 24, 2004,
which is a continuation of application No. 60/181,369,
filed on Feb. 8, 2000, now expired.**Publication Classification****Correspondence Address:****Davidson, Davidson & Kappel, LLC**
485 7th Avenue
14th Floor
New York, NY 10018 (UNITED STATES)(51) **Int. CL**
A61K 9/44 (2006.01)
A61K 9/20 (2006.01)
(52) **U.S. CL** 424/465; 424/10.2
(57) **ABSTRACT**(73) Assignee: **PURDUE PHARMA L.P.**, STAMFORD,
CO (US)(21) Appl. No.: **10/700,906**(22) Filed: **Nov. 4, 2003****Prior Publication Data**

(65) US 2006/0039970 A1 Feb. 23, 2006

Disclosed is an oral dosage form comprising (i) an opioid
agonist in releasable form and (ii) a sequestered opioid
antagonist which is substantially not released when the dos-
age form is administered intact, such that the ratio of the
amount of antagonist released from said dosage form after
tampering to the amount of said antagonist released from said
intact dosage form is about 4:1 or greater, based on the in-
vitro dissolution at 1 hour of said dosage form in 900 ml of
Simulated Gastric Fluid using a USP Type II (paddle) appa-
ratus at 75 rpm at 37 degrees C. wherein said agonist and
antagonist are interdispersed and are not isolated from each
other in two distinct layers.

APPENDIX E

Acknowledgement Receipt

The USPTO has received your submission at **11:52:43** Eastern Time on **26-AUG-2008** by Deposit Account: 500552.

\$ **430** fee paid by e-File via **RAM** with Confirmation Number: 6562.

eFiled Application Information

EFS ID	3838825
Application Number	10700906
Confirmation Number	1129
Title	Tamper-resistant oral opioid agonist formulations
First Named Inventor	Benjamin Oshlack
Customer Number or Correspondence Address	DAVIDSON, DAVIDSON & KAPPEL, LLC 14th Floor 485 Seventh Avenue New York NY 10018 US 2127361940
Filed By	Oleg Ioselevich
Attorney Docket Number	200.1133CON5
Filing Date	04-NOV-2003
Receipt Date	26-AUG-2008
Application Type	Utility under 35 USC 111 (a) (Pre-Grant Publication under 37 CFR 1.211 to 1.221)
Pre-Grant Filing Type	Republishion - Amended

Application Details

Submitted Files	Page Count	Document Description	File Size	Warnings
Specification.pdf	89		4231495 bytes	◆ PASS
		Document Description	Page Start	Page End
		Specification	1	77
		Claims	78	85
		Abstract	86	86
		Drawings-only black and white line drawings	87	89
sb0014_fill.pdf	5	Application Data Sheet	837077 bytes	◆ PASS
fee-info.pdf	2	Fee Worksheet (PTO-06)	31287 bytes	◆ PASS

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

If you need help:

- *Call the Patent Electronic Business Center at (866) 217-9197 (toll free) or e-mail EBC@uspto.gov for specific questions about Patent e-Filing.*
- *Send general questions about USPTO programs to the [USPTO Contact Center \(UCC\)](#).*
- *If you experience technical difficulties or problems with this application, please report them via e-mail to [Electronic Business Support](#) or call 1 800-786-9199.*

Electronic Patent Application Fee Transmittal

Application Number:	10700906			
Filing Date:	04-Nov-2003			
Title of Invention:	Tamper-resistant oral opioid agonist formulations			
First Named Inventor/Applicant Name:	Benjamin Oshlack			
Filer:	Oleg Ioselevich			
Attorney Docket Number:	200.1133CONS			
Utility under 35 USC 111(a) Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Request for voluntary publication or rep	1803	1	130	130
Publication fee for republication	1505	1	300	300
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				430

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	200.1133CON5
		Application Number	
Title of Invention	TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS		
<p>The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.</p> <p>This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.</p>			

Secrecy Order 37 CFR 5.2

- ☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Applicant Information:

Applicant 1				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
Mr.	Benjamin		Oshlack	
Residence Information (Select One) <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	New York	State/Province	NY	Country of Residence US
Citizenship under 37 CFR 1.41(b)		AU		
Mailing Address of Applicant:				
Address 1		351 East 84 street		
Address 2				
City	New York	State/Province	NY	
Postal Code	10028	Country	US	
Applicant 2				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
Mr.	Curtis		Wright	
Residence Information (Select One) <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	Norwalk	State/Province	CT	Country of Residence US
Citizenship under 37 CFR 1.41(b)		US		
Mailing Address of Applicant:				
Address 1		1 Jarvis Street		
Address 2				
City	Norwalk	State/Province	CT	
Postal Code	06851	Country	US	
Applicant 3				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
Mr.	J. David		Haddox	
Residence Information (Select One) <input checked="" type="radio"/> US Residency <input type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	Upper Stepany	State/Province	CT	Country of Residence US

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	200.1133CON5	
		Application Number		
Title of Invention	TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS			
Citizenship under 37 CFR 1.41(b)	US			
Mailing Address of Applicant:				
Address 1	23 Chadwick Court			
Address 2				
City	Upper Stepney	State/Province	CT	
Postal Code	06468	Country	US	
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.				

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).	
<input type="checkbox"/> An Address is being provided for the correspondence information of this application.	
Customer Number	23280
Email Address	

Application Information:

Title of the Invention	TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS		
Attorney Docket Number	200.1133CON5	Small Entity Status Claimed	<input type="checkbox"/>
Application Type	Nonprovisional		
Subject Matter	Utility		
Suggested Class (if any)		Sub Class (if any)	
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (if any)	3	Suggested Figure for Publication (if any)	

Publication Information:

<input type="checkbox"/> Request Early Publication (Fee required at time of Request 37 CFR 1.219)
Request Not to Publish. I hereby request that the attached application not be published under 35 U.S. C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.			
Please Select One:	<input checked="" type="radio"/> Customer Number	<input type="radio"/> US Patent Practitioner	<input type="radio"/> Limited Recognition (37 CFR 11.9)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	200.1133CON5
		Application Number	
Title of Invention	TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS		
Customer Number	23280		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.					
Prior Application Status		Patented		Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
	Continuation of	09781081	2001-02-08	6696088	2004-02-24
Prior Application Status		Expired		Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)		
09781081	Continuation of	60181369	2000-02-08		
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.					

Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).			
Remove			
Application Number	Country	Parent Filing Date (YYYY-MM-DD)	Priority Claimed
			<input type="radio"/> Yes <input type="radio"/> No
Additional Foreign Priority Data may be generated within this form by selecting the Add button.			

Assignee Information:

Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.			
Assignee 1			
If the Assignee is an Organization check here. <input checked="" type="checkbox"/>			
Organization Name	PURDUE PHARMA L.P.		
Mailing Address Information:			
Address 1	ONE STAMFORD FORUM		
Address 2			
City	STAMFORD	State/Province	CO
Country	US	Postal Code	06901
Phone Number		Fax Number	
Email Address			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	200.1133CON5
		Application Number	
Title of Invention	TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS		

Additional Assignee Data may be generated within this form by selecting the Add button.

Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/OLEG IOSELEVICH/		Date (YYYY-MM-DD)	2008-08-26
First Name	OLEG	Last Name	IOSELEVICH	Registration Number 56963

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.: US 7,682,632 B2

DATED: March 23, 2010

INVENTOR(S): Oshlack et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

On the title page, after item (65), the following section should be added:

-- **Related U.S. Application Data**

(63) Continuation of application No. 09/781,081, filed on
Feb. 8, 2001, now Pat. No. 6,696,088.

(60) Provisional application No. 60/181,369, filed on Feb. 8, 2000. --

MAILING ADDRESS OF SENDER: Oleg Ioselevich
Davidson, Davidson & Kappel, LLC
485 Seventh Avenue
New York, NY 10018

PATENT NO. US 7,682,632

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.